|
Market Closed -
Nasdaq
23:00:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.950 USD | +3.17% |
|
-14.47% | -39.63% |
| 10-16 | Top Premarket Gainers | MT |
| 10-13 | Alaunos Therapeutics Enters into Agreement and Plan of Merger with Velaris Therapeutics | CI |
| Market Cap | 4.95M 4.44M 4.08M 3.7M 6.91M 470M 7.04M 48.67M 19.54M 247M 18.59M 18.2M 780M | P/E 2024 |
-0.65x | P/E 2025 | -1.47x |
|---|---|---|---|---|---|
| Enterprise Value | 3.57M 3.2M 2.94M 2.66M 4.98M 339M 5.07M 35.06M 14.07M 178M 13.39M 13.11M 562M | EV / Sales 2024 |
195,938,500x | EV / Sales 2025 | 1,164,761,400x |
| Free-Float |
87.59% | Yield 2024 * |
-
| Yield 2025 | - |
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| TCRT | Delayed | |
CBOE
| TCRT | Real-time |
| 1 day | +3.17% |
| Manager | Title | Age | Since |
|---|---|---|---|
Holger Weis
CEO | Chief Executive Officer | 63 | 02/07/2025 |
| Director of Finance/CFO | 42 | 22/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Holger Weis
CHM | Chairman | 63 | 22/09/2023 |
Peter Harwin
BRD | Director/Board Member | 40 | 13/10/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/6/26 A | Free | Chief Executive Officer | 23,564 | 0.9275% | ||
| 10/6/26 A | Free | Director | 22,669 | 0.8923% | ||
| 10/6/26 A | Free | Director | 21,829 | 0.8592% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.17% | -14.47% | - | - | 4.95M | |
| -0.62% | -1.87% | +42.87% | +64.15% | 63.77B | |
| +0.35% | +3.20% | +14.40% | +81.76% | 56.37B | |
| +0.53% | +1.96% | +16.24% | +103.35% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +47.83% | 44.06B | |
| -0.33% | -1.93% | +19.28% | +98.80% | 42.11B | |
| +0.55% | +2.31% | +225.14% | +866.21% | 41B | |
| +3.27% | +47.96% | +112.84% | +96.58% | 34.92B | |
| +1.22% | -1.44% | +14.57% | +46.95% | 32.82B | |
| +0.89% | +20.55% | -40.62% | +349.24% | 24.7B | |
| Average | +0.62% | +5.34% | +47.58% | +194.99% | 39.43B | |
| Weighted average by Cap. | +0.18% | +5.44% | +47.99% | +176.67% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0.01 0.01 0.01 0.01 0.01 0.95 0.01 0.1 0.04 0.5 0.04 0.04 1.58 | 0 0 0 0 0.01 0.47 0.01 0.05 0.02 0.25 0.02 0.02 0.79 |
| Net income | -4.68M -4.19M -3.85M -3.49M -6.53M -444M -6.65M -45.97M -18.45M -234M -17.56M -17.19M -737M | -4.18M -3.74M -3.44M -3.12M -5.83M -397M -5.94M -41.03M -16.47M -209M -15.67M -15.34M -658M |
| Net Debt | -1.09M -977K -899K -814K -1.52M -104M -1.55M -10.72M -4.3M -54.49M -4.09M -4.01M -172M | -1.38M -1.24M -1.14M -1.03M -1.93M -132M -1.97M -13.61M -5.46M -69.18M -5.2M -5.09M -218M |
Employees
1
| Date | Price | Change |
|---|---|---|
| 30/10/26 | $1.950 | +3.17% |
| 29/10/26 | $1.890 | -11.27% |
| 28/10/26 | $2.130 | +3.40% |
| 27/10/26 | $2.060 | -3.29% |
| 26/10/26 | $2.130 | -6.58% |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- TCRT Stock
Select your edition
All financial news and data tailored to specific country editions
